In this current review, we analyzed data from 5,256 patients with type 1 diabetes who used SGLT2 inhibitors, to look more closely at the risks and benefits of this drug in type 1 diabetes. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.